These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 28902390)
41. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease. Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727 [TBL] [Abstract][Full Text] [Related]
42. Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. von Tresckow B; Plütschow A; Fuchs M; Klimm B; Markova J; Lohri A; Kral Z; Greil R; Topp MS; Meissner J; Zijlstra JM; Soekler M; Stein H; Eich HT; Mueller RP; Diehl V; Borchmann P; Engert A J Clin Oncol; 2012 Mar; 30(9):907-13. PubMed ID: 22271480 [TBL] [Abstract][Full Text] [Related]
43. Hodgkin Lymphoma in Adolescent and Young Adults: Real-World Data from a Single Tertiary Cancer Center in India. Nayak L; Jain H; Bonda A; Epari S; Laskar S; Gokarn A; Shet T; Gujral S; Khanna N; Bagal B; Punatar S; Goda J; Thorat J; Rengaraj K; Sengar M J Adolesc Young Adult Oncol; 2021 Oct; 10(5):581-587. PubMed ID: 33090916 [No Abstract] [Full Text] [Related]
44. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Pavone V; Ricardi U; Luminari S; Gobbi P; Federico M; Baldini L; Iannitto E; Ucci G; Marcheselli L; Orsucci L; Angelucci E; Liberati M; Gavarotti P; Levis A; Ann Oncol; 2008 Apr; 19(4):763-8. PubMed ID: 18180244 [TBL] [Abstract][Full Text] [Related]
45. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma]. Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946 [TBL] [Abstract][Full Text] [Related]
46. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. Somers R; Carde P; Henry-Amar M; Tarayre M; Thomas J; Hagenbeek A; Monconduit M; de Pauw BE; Breed WP; Verdonck L J Clin Oncol; 1994 Feb; 12(2):279-87. PubMed ID: 7509381 [TBL] [Abstract][Full Text] [Related]
47. Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy. Bartlett NL Am Soc Clin Oncol Educ Book; 2013; ():374-80. PubMed ID: 23714551 [TBL] [Abstract][Full Text] [Related]
49. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Kelly KM; Cole PD; Pei Q; Bush R; Roberts KB; Hodgson DC; McCarten KM; Cho SY; Schwartz C Br J Haematol; 2019 Oct; 187(1):39-48. PubMed ID: 31180135 [TBL] [Abstract][Full Text] [Related]
50. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). Johnson PW; Radford JA; Cullen MH; Sydes MR; Walewski J; Jack AS; MacLennan KA; Stenning SP; Clawson S; Smith P; Ryder D; Hancock BW; J Clin Oncol; 2005 Dec; 23(36):9208-18. PubMed ID: 16314615 [TBL] [Abstract][Full Text] [Related]
51. [Our experiences in treating patients with Hodgkin disease in the last decade]. Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575 [TBL] [Abstract][Full Text] [Related]
52. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976 [TBL] [Abstract][Full Text] [Related]
53. Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report. Fernández KS; Schwartz CL; Chen L; Constine LS; Chauvenet A; de Alarcón PA Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28612375 [TBL] [Abstract][Full Text] [Related]
54. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group. Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM; Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286 [TBL] [Abstract][Full Text] [Related]
55. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary. McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859 [TBL] [Abstract][Full Text] [Related]
56. Bulky mediastinal Hodgkin's disease: results of a combined modality approach (ABVD/MOPP alternating chemotherapy plus radiation therapy). De Lena M; Ditonno P; Lorusso V; Timurian A; Pellecchia A; Brandi M; Berardi F; Marzullo F Haematologica; 1993; 78(4):230-5. PubMed ID: 7507457 [TBL] [Abstract][Full Text] [Related]
57. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]
58. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848 [TBL] [Abstract][Full Text] [Related]
59. ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥ 4 baseline): final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Mounier N; Brice P; Bologna S; Briere J; Gaillard I; Heczko M; Gabarre J; Casasnovas O; Jaubert J; Colin P; Delmer A; Devidas A; Bachy E; Nicolas-Virelizier E; Aoudjhane A; Humbrecht C; Andre M; Carde P; Ann Oncol; 2014 Aug; 25(8):1622-8. PubMed ID: 24827123 [TBL] [Abstract][Full Text] [Related]
60. Serum levels of soluble CD30 improve International Prognostic Score in predicting the outcome of advanced Hodgkin's lymphoma. Zanotti R; Trolese A; Ambrosetti A; Nadali G; Visco C; Ricetti MM; Benedetti F; Pizzolo G Ann Oncol; 2002 Dec; 13(12):1908-14. PubMed ID: 12453859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]